



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

22 04 2004

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

REC'D 21 JUL 2004

WIPO PCT

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03388023.8

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Anmeldung Nr:
Application no.: 03388023.8
Demande no:

Anmeldetag:
Date of filing: 23.04.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Ferring B.V.
Polaris Avenue 144
2132 JX Hoofddorp
PAYS-BAS
Ferring Pharmaceuticals A/S
Kay Fiskers Plads 11
2300 Copenhagen S
DANEMARK

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

High drug load mesalazine sachet

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

A61K9/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

HIGH DRUG LOAD MESALAZINE SACHET

Field of the Invention

The present invention concerns a pharmaceutical formulation comprising a high load of active drug.

5

In particular, it concerns a particulate pharmaceutical formulation comprising a high load (i.e. with high weight % active drug) of 5-aminosalicylic acid (5-ASA, mesalamine, mesalazine) for oral administration as well
10 as a method for producing it and a sachet for the formulation.

Technical Background

Oral pharmaceutical formulations comprising mesalazine
15 are known, which are either tablets or granulate. The granulate may be packed in sachets. For the purposes of the present invention a "sachet" will refer to an envelope or bag for a granulate, while "granulate" refers to particles, granulate or spheronised particles.

20

Presently, tablets containing 250 or 500 mg mesalazine are known. Tablets of 250 mg typically weigh about 540 mg, i.e. they have a drug load of $(250/540)\%$ by weight = 46% by weight. Tablets containing up to 84 % by weight
25 mesalazine have been described in the patent application WO 00/44353 with the title "Pharmazeutische Zusammensetzungen".

For sachets, Dr. Falk Pharma has launched a product which
30 claims to contain 500 mg mesalazine in a 930 mg sachet, corresponding to a drug load of 54% by weight.

Presently up to 4 g of mesalazine are often prescribed for the daily treatment of intestinal bowel diseases,
35 such as Crohn's disease and Ulcerative Colitis.

If 4 g of mesalazine is administered in 250 mg tablets, the patient needs to swallow 16 tablets a day.

Alternatively, 500 mg tablets may be administered, but
5 with a drug load in the 50% range, the tablets will weigh about 1 g each, which many patients find rather large to swallow.

There exists a need to provide a product which allows
10 administering large daily doses of drug without adversely affecting patient compliance.

Methods for manufacturing oral pharmaceutical formulations comprising mesalazine on an industrial scale
15 are known. However, known methods of manufacture necessitate a high number of production steps to achieve a product having desirable release characteristics. This leads to cumbersome and expensive manufacture.

20 Disclosure of the Invention

These problems and others mentioned below are addressed by aspects of the invention.

According to an aspect, the present invention concerns an
25 oral pharmaceutical formulation, preferably for a sachet, comprising an amount of mesalazine selected among the group consisting of 55; 60; 65; 70; 75; 80; 85; 90; 92; 94 and 96 % by weight. According to a preferred aspect, the formulation comprises 92 - 98, preferably 94 - 96, %
30 by weight mesalazine.

These aspects provide a high load pharmaceutical composition.

35 For the purposes of the present invention "mesalazine" also encompasses pharmaceutically acceptable salts and esters thereof, such as those mentioned in WO 97/23199 p.

15, l. 17 - p. 6, l. 12, as well as prodrugs, such as balsalazide.

The formulation is preferably in the form of a
5 particulate material, e.g. granulate, spheres, pellets, particles, preferably granulate.

According to an aspect, the present invention concerns a pharmaceutical formulation further comprising a
10 pharmaceutically acceptable binder, preferably Povidone, in an amount selected among the group consisting of 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; and 12 % by weight. According to a preferred aspect, the formulation comprises 1 - 10, preferably 2 - 8; more preferred 3 - 7; preferably 4 - 6;
15 most preferred 5 % by weight Povidone.

The pharmaceutically acceptable binder may comprise any acceptable binder such as Acacia, Gelatin, Hydroxypropyl cellulose, Hydroxypropylmethyl cellulose,
20 Methylcellulose, Polyethylene glycol (PEG), Povidone, Sucrose, Starch or a mixture of any of these. Povidone (Polyvinylpyrrolidone, PVP) is preferred.

According to an aspect, the present invention concerns a
25 pharmaceutical formulation further comprising a coating.

The coating should preferably comprise a release modifying agent, such as ethylcellulose, carnauba wax, shellac or a mixture of any of these. Ethylcellulose is
30 preferred.

The selected coating depends inter alia on the desired release pattern. It may be chosen from rate limiting barrier materials, e.g. enteric or delayed coating
35 material, such as polymethacrylate, commercially available in the form of Eudragits, e.g. Eudragit NE 40 D

or Eudragit L 100. When a semi-permeable polymer is used, ethyl cellulose is the most preferred coating.

According to an aspect, the formulation is a modified
5 release formulation, preferably an extended release formulation.

According to an aspect, the present invention concerns a pharmaceutical formulation essentially consisting of
10 mesalazine, a pharmaceutically acceptable binder and a coating.

According to an aspect, the present invention concerns a pharmaceutical formulation having in vitro release
15 characteristics of mesalazine of at least 40, 50, 60, 70, 80, or 90 % released after 240 min, of the total amount of mesalazine in the formulation, measured in a model system using a USP Paddle System 2 operated at 37°C with stirring at 100 rpm.

20 According to an aspect, the present invention concerns a pharmaceutical formulation having in vitro release characteristics of mesalazine of

- a) 5 - 25 % released after 15 min;
- 25 b) 30 - 70 %, preferably 40 - 60 %, released after 90 min; and
- c) 75 - 100 % released after 240 min;

of the total amount of mesalazine in the formulation, measured in a model system using a USP Paddle System 2
30 operated at 37°C with stirring at 100 rpm.

The dissolution parameters for the model system were:
Dissolution medium: 1000 ml deaerated 0.1 M sodium phosphate buffer pH 7.5.

35 Apparatus: USP 23 Paddle method (Apparatus 2)
Shaft rotation speed: 100 rpm. 1 g sachets were used for experiments.

- as measured under the conditions listed above.

The similarity factor f_2 is defined as

$$f_2 = 50 \log \left\{ \left[1 + (1/n) \sum_{i=1}^n (R_i - T_i)^2 \right]^{0.5} * 100 \right\}$$

wherein n is the number of time points, $R(t)$ is the mean percent active ingredient dissolved of the standard, and $T(t)$ is mean percent active ingredient dissolved of the formulation according to the invention. The similarity factor is usually considered satisfactory if in the range 50 - 100, but may for the purposes of the present invention be even smaller.

According to a second preferred aspect, the present invention concerns a pharmaceutical formulation having a similarity factor f_2 above a number selected from 25, 30, 35, 40, 45, 50, 55, 60, 65, and 70, as compared to a standard having the in vitro release characteristics of mesalazine of

- d) 21 % released after 15 min;
e) 68 % released after 90 min; and
f) 94 % released after 240 min;

as measured under the conditions listed above.

a) mixing mesalazine with granulation liquid;
b) obtaining granulate by granulating,
10 compacting or extruding;
c) drying the granulate;
d) adjusting the size of the granulate as
 necessary; and
e) sieving the granulate as necessary;
15 characterised in the additional step of:
f) coating the granulate;
and optionally further:
g) sieving the coated granulate;
h) air purging the coated granulate.

25 Other suitable package forms are containers usually used
for oral formulations.

30 According to an aspect of the invention a pharmaceutical composition is provided being produced without spheronization. The composition is thus obtainable without spheronization. Thereby the need for a
35 spheronization aid is eliminated, allowing the pharmaceutical composition to have a high drug load.

Spheronization has been used to obtain a reproducible product on an industrial scale, the product being visually appealing and easy to administer, leading to high patient compliance.

5

It has until the present invention been considered necessary to spheronise mesalazine drugs in order to obtain a visually appealing and easily administrable sachet product. Spheronisation implies the use of a spheronization aid or enhancer, such as microcrystalline cellulose. The presence of a spheronization aid leads to drug loads lower than obtainable with the present invention.

15 There exists a demand for a dust-free high load pharmaceutical composition. A pharmaceutical formulation meeting these criteria is achieved according to an aspect of the invention without spheronization. Such composition may be provided by obtaining a granulate. A granulate may be obtained by granulating, compacting or extruding, in order to achieve a product which is visually appealing to a person to whom said pharmaceutical formulation is administered. Compacting may be performed e.g. by roll compacting. The granulate is preferably obtained by
25 extruding.

According to a certain preferred aspect of the present invention, the pharmaceutical composition is obtained according to co-pending patent application PCT/DK01/00677 with the title "Method for the preparation of a
30 pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of Ulcerative Colitis and Crohn's Disease", with modifications. The modifications comprise that the coating should be adapted according to the present invention, and that after coating, sieving and nitrogen purging, the obtained granulate are packed
35 in sachets, without the need for further excipients (cf.

5

10

15

20

25

30

35

than 85 % and most preferably more than 90 % of the granules have a particle size from 850 μm to 1000 μm .

According to an aspect, the present invention concerns the method, wherein the coating step f) is performed with ethylcellulose.

According to an aspect, the present invention concerns the method, wherein the coating step f) is performed by spraying with an amount of coating material, adjusted according to the specific surface area, to be in the range 0.09 - 0.17 mg/cm^2 , preferably 0.11 - 0.15 mg/cm^2 , more preferred 0,12 - 0,14 mg/cm^2 , followed by drying. These amounts have been found suitable for coating with ethylcellulose.

It has been discovered that the desired release profile may be obtained by adjusting the amount of coating material used according to the specific surface area.

The specific surface area may be measured by permeametry according to "Evaluation of a permeametry technique for surface area measurement of coarse particulate materials, International Journal of Pharmaceutics, Eriksson et al., 1990, 63, p. 189-199".

Granulate obtained according to co-pending patent application PCT/DK01/00677, preferably with modifications according to the present invention, is especially preferred, as it has a smooth surface facilitating measurement of specific surface area as well as subsequent coating.

In order to be able to determine the amount of coating that has to be applied to the granules the surface area is measured. Based on the measured correlation between the amount of coating per surface area and the

5

10

15

20

25

30

35

- The present sachet may be used for any pharmaceutical formulation, but is especially suitable for storing pharmaceuticals comprising sensitive compounds such as mesalazine.

- Mesalazine is sensitive to humidity, atmospheric air and/or light. A sachet for a product containing mesalazine should therefore preferably provide a barrier to humidity, atmospheric air and light. The sachet should also be easy to open for a patient, preferably without the use of additional tools, such as scissors. It has

been a problem to provide a sachet with the necessary barrier properties without sacrificing the possibility of tearing open the sachet with human fingers. Further, existing sachets tend to suffer from the build up of static electricity. Preferably, a sachet should be easy to manufacture, easy to fill, easy to empty, and have an appealing look to improve patient compliance.

This aspect provides a sachet giving long storage stability for a pharmaceutical composition contained therein, e.g. where the active pharmaceutical ingredient is mesalazine. Further, the sachet is easy to tear and static electricity is eliminated, providing for a sachet which may be emptied completely for its contents. The combination of the sachet and the oral formulation according to the present invention provides for little build up of static electricity.

According to an aspect, the present invention concerns the sachet, wherein the bonding layer ii) preferably has a weight per unit area of 6-20 g/m², preferably 9-15 g/m², more preferred 12 g/m²; the barrier layer iii) preferably has a thickness of 6-30 µm, more preferred 7-25 µm, preferably 9-25 µm, more preferred 8-20 µm, preferably 9-15 µm, more preferred 12 µm; and/or the sealing layer iv) preferably has a weight per unit area of 10-100 g/m², more preferred 15-75 g/m², preferably 20-50 g/m², more preferred 30-40 g/m², most preferred 35 g/m².

The outer paper i) has in a preferred embodiment a weight per unit area of 10-100 g/m², preferably 30-70 g/m², most preferred 50 g/m².

According to an aspect, the present invention concerns the use of the sachet for a pharmaceutical composition according to the invention.

The sachet has proven suitable for storing the pharmaceutical compositions according to the invention.

According to an aspect, the present invention concerns
5 the use of the sachet for medical purposes.

According to an aspect of the present invention it is not limited to the use of mesalazine as the active ingredient, but also relates to other active ingredients,
10 such as the ingredients mentioned in WO 00/44353, p. 12-16. Other low potent active ingredients are suitable for the present invention. Especially ibuprofen is envisioned as replacing mesalazine.

15 According to an aspect of the present invention further excipients may be comprised in the composition according to the invention, such as fillers, disintegrants, pH adjusters, or surfactants. Such excipients are well known from the literature, see e.g. WO 00/44353, p. 16-20, for
20 a number of suitable excipients.

Examples

Unless otherwise stated, all percentages are in % by weight.

25

Example 1

A batch for the production of 180,000 sachets of prolonged release granules was provided as follows.

30	<u>Constituents</u>	<u>Quantity</u>	<u>Specification</u>
	Mesalazine	180 kg	Ferring
	Povidone	9 kg	Ph. Eur.
	Water, purified	33,3 kg**	Ph. Eur.
	Ethylcellulose	1,9 kg***	Ph. Eur.
35	Acetone	188 kg**	Ph. Eur.

** Evaporates during production.

*** The amount of ethylcellulose was adjusted to ensure the desired dissolution profile of the finished product. Ph. Eur. refers to the current edition at the time of filing of the present application.

5

The manufacturing method follows closely the manufacturing method described in co-pending patent application PCT/DK01/00677, with some exceptions. The amount and type of ingredients is adjusted, and in particular the amount of ethylcellulose is reduced to obtain the desired dissolution profile. In this example no tablets were made, so excipients for this purpose are not included, no dry blending is performed after the air purging, and no tableting performed. The granulate product resulting from the present process is therefore different from the tablet of said application.

15

The manufacturing process for the formulation can be divided into 9 steps:

20

1. Preparation of granulation liquid
2. Granulation of Mesalazine with water and PVP
3. Extrusion
4. Fluid bed drying
- 25 5. Milling
6. Sieving
7. Coating
8. Sieving
9. Air purging

30

Equipment for the production	Function
NICA Extruder E220	Extrusion
Rotostat T05	Blending
35 NIRO Fluid bed dryer	Drying
Quadro Comil U10	Milling
Mogensen sieve	Sieving

Hüttlin Kugelcoater HKC 400	Coating
Prodima rotation sieve	Sieving
Purging unit	Air purge

5 Step 1:

For one batch of granulation liquid water is filled into a Müller drum. The mixer is put into position and started. Polyvinylpyrrolidone (PVP) is slowly sprinkled onto the water and the mixer is allowed to run a fixed
10 time until all PVP is dissolved.

Step 2 and 3:

Mesalazine is placed in a vibrating Prodima hopper and by the use of a conveyor the mesalazine is transported up to
15 a weight belt feeder dosing the mesalazine into the continuous Niro line. In the first part of the Niro line the mesalazine and the water solution of PVP are mixed to a wet mass before being transported into the extruder. After extrusion of the wet mass of mesalazine and
20 PVP/water through a screen mesh 0.9 mm, the granules fall directly into the fluid bed dryer.

Step 4:

The fluid bed dryer is divided into two main sections. In
25 the first section, the granules are dried on the surface to prevent them from sticking together. In this section of the fluid bed, a random mixing of the granules takes place. After a certain residence time, the granules are moved into the second part of the dryer where the actual
30 drying takes place. In the second part of the dryer the granules are guided by the use of the drying air through the dryer (special pattern of holes in the gill plate). When the granules are dry they are allowed to fall into a drum placed under the fluid bed. The fluid bed is
35 constructed in such a way that the overall dwelling time in the fluid bed is approximately 2½ hours.

Step 5:

The drums containing the dry granules are placed upside down on top of the mill and the granules are gently milled using a screen, which will only break the granules that are too long. After passing the mill, the granules are allowed to fall into a drum.

Step 6:

Due to the fact that the milling process generates a small amount of undersized granules, the granules are sieved using a Mogensen vibration sieve. Granules, which pass the screen 0.8 mm, are discarded or can be collected for reprocessing stored in airtight, labelled containers.

Step 7:

200 kg of sieved granules are coated in a Kugel coater (fluid bed system) with a coating liquid consisting of ethyl cellulose dissolved in acetone.

In order to be able to determine the right amount of ethylcellulose necessary to apply on the granules to get the desirable dissolution rate profile, the surface area of the granules is measured prior to the coating process. The prediction of the quantity of coating that is necessary to apply on the granules has been developed based on the fact that there is a correlation between the amount of coating per surface area and the dissolution rate of the granules.

When the coating step was performed in a HKC 400 Hüttlin Kugel coater and followed by production scale sieving, release characteristics according to the invention, as measured as released % of total amount of mesalazine or according to the first preferred aspect as defined by the similarity factor, was achieved when the amount of ethylcellulose was adjusted to 0.13 mg/cm².

After finishing the coating process, the coated granules are loaded into a drum for further processing.

Step 8:

- 5 After the coating process, the coated granules are sieved in a Prodima rotation sieve. Large lumps are discarded.

Step 9:

- 10 After sieving the batch of coated granules, they are divided into two drums for purging with compressed air or nitrogen. The granules are purged for 6 - 14 hours. This purging process is necessary to reduce the amount of residual solvent (acetone) in the coated granules.

- 15 This batch gave granulate with the following approximate composition:

mesalazine	94,3%
Povidone	4,7%
Ethylcellulose	1,0%

20

The granulate was subsequently filled into sachets.

The material of the sachets had the following composition:

- | | | |
|----|---------------------------|---------------------|
| 25 | Paper, claycoated | 50 g/m ² |
| | Polyethylene, low density | 12 g/m ² |
| | Aluminium foil | 12 µm |
| | Polyethylene, low density | 35 g/m ² |

- 30 For the present example 12 g/m² PE corresponds to 13 µm, and 35 g/m² PE corresponds to 38 µm. The material had a grammage of 129 g/m². The permeability to water vapour was <0.05 g/m², 24 h, 25°C, 75% RH, and to O₂ <0.05 ml/m², 24 h, atm, 23°C, 75% RH.

- 35 The sachets were folded around the filling tube of a filling/sealing station, such that the paper was on the outside of the sachet, and then sealed lengthwise, with a

All citations are incorporated in their entirety by reference.

CLAIMS

- [illegible]

factor f_2 above 30, preferably above 40, more preferred above 50, as compared to a standard having the in vitro release characteristics of mesalazine of

- 5 a) 12 % released after 15 min;
 b) 50 % released after 90 min; and
 c) 85 % released after 240 min;
 as measured under the conditions of claim 5.

10 7. Pharmaceutical formulation according to any of the preceding claims, wherein said pharmaceutical formulation is packed in a sachet.

15 8. Method for manufacturing a pharmaceutical formulation according to any of the preceding claims, comprising the steps:
 a) mixing mesalazine with granulation liquid;
 b) obtaining granulate by granulating,
20 compacting or extruding;
 c) drying the granulate;
 d) adjusting the size of the granulate as necessary; and
 e) sieving the granulate as necessary;
25 characterised in the additional step of:
 f) coating the granulate;
 and optionally further:
 g) sieving the coated granulate;
 h) air purging the coated granulate.

30 9. Method according to the preceding claim, wherein said coated granulate are packed in a sachet.

35 10. Method according to claim 8 or 9, wherein said granulation liquid consists of Povidone dissolved in water.

- [illegible]

5

10

- 15

20

06-089_FBI had no further lead as at 07-07-20

ABSTRACT

The present invention is directed to a high drug formulation having desirable properties in terms of ease of manufacture and visual appearance as well as a sachet for the formulation.

PCT/EP2004/004280

